France-based Innate Pharma SA filed with the U.S. Securities and Exchange Commission for a $100 million IPO on the Nasdaq global market.
The company, which develops therapeutic antibodies that harness the immune system to fight cancer, is offering its American depositary shares, representing ordinary shares in the U.S. and a concurrent private placement of its ordinary shares in Europe and countries outside the U.S.
The company will list on the Nasdaq Global Market under the IPHA ticker. The company's ordinary shares are listed on the Euronext Paris under the ticker IPH.
Innate's pipeline of antibodies includes Lumoxiti, licensed from AstraZeneca PLC and approved by the U.S. Food and Drug Administration in September 2018 for the treatment of a type of blood cancer.
Citigroup, SVB Leerink and Evercore ISI are joint book-runners for the U.S. offering, and Citigroup is the global coordinator for the European private placement.
